Friday, Dec 18 2020 | Time 08:24 Hrs(IST)
image
  • Boeing’s 737 MAX jet clears key hurdle in bid to return to skies in Canada
  • PM to address MP’s ryots
  • Star Wars actor Jeremy Bulloch dies at age of 75
  • Star Wars actor Jeremy Bulloch dies at age of 75
  • Star Wars actor Jeremy Bulloch dies at age of 75
  • US launches phase 3 trial of 2 new antibody treatments for COVID-19: Health Dept
  • Twitter to introduce new function in 2021 to help users identify bots: Blog
  • US stocks rally with all 3 key indexes hitting record highs based on stimulus expectations
  • Both hostage-taker, his wife found dead by Gendarmes near Paris: Reports
  • MP CM’s focus on betterment of hawkers
  • After CBDT report and ECI order, MP CM assures action
  • Gutka worth around Rs 7 lakh seized in Nashik, 1 held
  • Avg hike of 1 98 pc in MP power rates
  • War against COVID-19: MP’s body count rises to 3,442
WorldPosted at: Dec 18 2020 7:19AM


US launches phase 3 trial of 2 new antibody treatments for COVID-19: Health Dept

WASHINGTON, Dec 18 (Sputnik) The United States announced phase 3 clinical trials of two experimental drugs to treat hospitalized COVID-19 patients when combined with existing treatments, the National Institute for Allergy and Infectious Diseases (NIAID) said in a press release.
"The trials are part of the ACTIV-3 master protocol, which has an adaptive design allowing investigators to add new sub-studies of additional investigational agents," the release said on Thursday.
ACTIV-3 refers to a NIAID protocol designed to test treatments using multiple drugs administered simultaneously, with trial participants either receiving the investigative agent or a placebo in addition to standard treatments, which typically include the antiviral drug remdesivir, the release said.
One sub-study will evaluate VIR-7831, a monoclonal antibody developed by GlaxoSmithKline in the United Kingdom and Vir Biotechnology in the United States. The other sub-study will evaluate a combination of BRII-196 and BRII-198, two monoclonal antibodies manufactured by Brii Biosciences in Beijing and the state of North Carolina, the release added. Monoclonal antibodies are grown in a lab as copies of naturally occurring proteins produced by the human immune system.
The protocol allows researchers to evaluate each antibody in a small group of volunteers, and then to enroll a larger group of volunteers if the antibody appears safe and effective. Initially, researchers will enroll approximately 450 volunteers who have been hospitalized with mild to moderate COVID-19 and fewer than 13 days of symptoms, the release said.
If the experimental drug appears to be safe and effective, each sub-study will enroll an additional 700 people, half receiving the drug and half a placebo. The primary endpoint of the trial is the participants’ sustained recovery for 14 days after release from the hospital, the release added.
The United States previously authorized use of other antibody-based COVID-19 treatments, including one developed by Regeneron that was given to President Donald Trump.
SPUTNIK ASN
Tags: #US launches phase 3 trial of 2 new antibody treatments for COVID-19: Health Dept
More News
Bangladesh records 36 more deaths from Covid-19

Bangladesh records 36 more deaths from Covid-19

17 Dec 2020 | 8:06 PM

Dhaka, Dec 17 (UNI) Thirty-six more people died from Covid-19 in Bangladesh in the past 24 hours, taking the death toll to 7,192.

see more..
Argentina to receive 600,000 Russian Sputnik V vaccine doses

Argentina to receive 600,000 Russian Sputnik V vaccine doses

17 Dec 2020 | 7:40 PM

Buenos Aires, Dec 17 (UNI) Argentina will receive first doses of the Russian Sputnik V vaccine against Covid-19 on December 23, Argentinian TN channel reported, citing governmental sources.

see more..

Saudi Arabia starts Corona vaccination

17 Dec 2020 | 5:25 PM

Riyadh, Dec 17 (UNI) Saudi Arabia started on Thursday the Novel Coronavirus vaccination process.

see more..

Malaysia reports 1,220 fresh nCoV cases, 3 deaths

17 Dec 2020 | 5:21 PM

Kuala Lumpur, Dec 17 (UNI) Malaysia reported 1,220 fresh Novel Coronavirus cases, bringing the national total to 89,133, the health ministry said on Thursday, .

see more..

ESA appoints Aschbacher as new director general

17 Dec 2020 | 4:34 PM

Moscow, Dec 17 (UNI) The European Space Agency (ESA) has appointed Josef Aschbacher, as new director general, the ESA said on Thursday, adding that he would assume the role in July 2021.

see more..
image